Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

BACKGROUND: Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF)....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diabetol
Glavni autori: Bode, David, Semmler, Lukas, Wakula, Paulina, Hegemann, Niklas, Primessnig, Uwe, Beindorff, Nicola, Powell, David, Dahmen, Raphael, Ruetten, Hartmut, Oeing, Christian, Alogna, Alessio, Messroghli, Daniel, Pieske, Burkert M., Heinzel, Frank R., Hohendanner, Felix
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792219/
https://ncbi.nlm.nih.gov/pubmed/33413413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01208-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items